ASH 2022: Recent Advances in Chronic Myeloid Leukemia

EP: 1.ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

Now Viewing

EP: 2.ASH 2022: Recent Advances in Chronic Myeloid Leukemia

EP: 3.Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting

Data from the following clinical trials are discussed:

• 620: Three-Year Update from the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
• 333: Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
• 3009: Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
• 4339: Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.